WVE — Wave Life Sciences Cashflow Statement
0.000.00%
Last trade - 00:00- $611.15m
- $438.10m
- $113.31m
Annual cashflow statement for Wave Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -194 | -150 | -122 | -162 | -57.5 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 21.1 | 16.2 | 18.8 | 20.7 | 14 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -23.3 | 9.65 | 7.01 | 6.72 | 19.1 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -188 | -116 | -89 | -128 | -19.4 |
| Capital Expenditures | -3.92 | -1.34 | -0.56 | -1.36 | -1.11 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | 0.106 | 0 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -3.92 | -1.34 | -0.56 | -1.25 | -1.11 |
| Financing Cash Flow Items | — | 0.171 | 0.608 | 0.372 | 0.748 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 164 | 155 | 55.8 | 67.2 | 133 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -27.6 | 37.3 | -33.9 | -62.1 | 112 |